Page last updated: 2024-11-08

1-methyl-3-ethylimidazolium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-3-ethylimidazolium: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-ethyl-3-methylimidazolium : A 1-alkyl-3-methylimidazolium in which the alkyl substituent at C-1 is ethyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID174076
CHEMBL ID3305904
CHEBI ID61326
SCHEMBL ID34728
MeSH IDM0139576

Synonyms (24)

Synonym
meetimcl
1-ethyl-3-methylimidazolium
[c2mim]
[emim]
1-methyl-3-ethylimidazolium
1-ethyl-3-methyl-1h-imidazol-3-ium
CHEBI:61326 ,
inchi=1/c6h11n2/c1-3-8-5-4-7(2)6-8/h4-6h,3h2,1-2h3/q+1
njmwoufkyknwdw-uhfffaoysa-
1-ethyl-3-methylimidazol-3-ium chloride
1-ethyl-3-methylimidazol-3-ium
NCGC00248716-01
meetimcl-alcl3
unii-tve1d62mak
tve1d62mak ,
65039-03-4
1-methyl-3-ethylimidazolium tetrachloroaluminate
SCHEMBL34728
DTXSID9048069
CHEMBL3305904
1h-imidazolium, 3-ethyl-1-methyl-
3-ethyl-1-methyl-1h-imidazolium
3-ethyl-1-methylimidazolium
Q27131035

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results of our study has proved the negative impact of ILs on the tested plants and the toxic effect of imidazolium salts was dependent primarily on the applied ionic liquids concentration."( The role of the anion in the toxicity of imidazolium ionic liquids.
Bałczewski, P; Biczak, R; Pawłowska, B; Rychter, P, 2014
)
0.4
" The literature (through the analysis of toxicity of the anion and the cation separately) suggests that [C2mim][OAc] is a relatively safe choice for industrial applications."( Scaling-Up Ionic Liquid-Based Technologies: How Much Do We Care About Their Toxicity? Prima Facie Information on 1-Ethyl-3-Methylimidazolium Acetate.
Berton, P; Ostadjoo, S; Rogers, RD; Shamshina, JL, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Furthermore, in comparison with the pure cellulose film, the water retention of the composite film increased and the water absorption rate decreased obviously, which meant that the resistance of the material to changes in environmental humidity was greatly improved."( Study on the Preparation of Ionic Liquid Doped Chitosan/Cellulose-Based Electroactive Composites.
He, B; Li, J; Qian, L; Wang, F; Xie, C, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"From gestation days (GD) 6-16, mated CD-1 mice were orally dosed with one of the following: 1,000, 2,000, or 3,000 mg/kg/day [C(2)mim]Cl; 113, 169, or 225 mg/kg/day [C(4)mim]Cl; 50, 75, or 100 mg/kg/day [C(10)mim]Cl; or the vehicle only."( A comparison of the effects of prenatal exposure of CD-1 mice to three imidazolium-based ionic liquids.
Bailey, MM; Beaird, J; Di Bona, KR; Henson, MB; Hood, RD; Hough, WL; Jernigan, PL; Lockhard, JE; Lovich, AN; Rasco, JF; Rogers, RD; Sherrill, J; Sturdivant, J; Swatloski, RP, 2010
)
0.36
"Fetal weight was significantly decreased in the two highest dosage groups exposed to [C(4)mim]Cl and [C(10)mim]Cl in comparison with their controls, but the [C(2)mim]Cl treated groups were not affected."( A comparison of the effects of prenatal exposure of CD-1 mice to three imidazolium-based ionic liquids.
Bailey, MM; Beaird, J; Di Bona, KR; Henson, MB; Hood, RD; Hough, WL; Jernigan, PL; Lockhard, JE; Lovich, AN; Rasco, JF; Rogers, RD; Sherrill, J; Sturdivant, J; Swatloski, RP, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-alkyl-3-methylimidazoliumAn imidazolium ion with an alkyl substituent at the 1-position and a methyl substituent at the 3-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (238)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.42)18.7374
1990's0 (0.00)18.2507
2000's20 (8.40)29.6817
2010's193 (81.09)24.3611
2020's24 (10.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.63 (24.57)
Research Supply Index5.48 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other237 (98.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]